Shanghai Releases New Guidelines to Accelerate State-Owned Capital Fund-Led M&A Paradigm

State-owned capital has become a key force in the private equity investment market. On April 7, with the approval of the Shanghai Municipal People’s Government, the Shanghai State-owned Assets Supervision and Administration Commission (SASAC) released the “Guiding Opinions on Further Promoting the High-Quality Development of Private Equity Investment Funds by Enterprises Under the Supervision of the Municipal SASAC,” further accelerating a new paradigm for state-owned capital fund mergers and acquisitions.

A rather typical example is Kanghua Biological (300841.SZ). On April 20, Kanghua Biological disclosed its first quarterly report since the Shanghai Biopharmaceutical M&A Fund took control. In Q1 2026, operating revenue increased by 25% year-on-year, net profit attributable to shareholders of the parent company rose by 32% year-on-year, and operating cash flow turned positive year-on-year, gradually revealing a turning point in periodic performance.

This “inflection point” is a direct manifestation of the in-depth post-investment management led by Shanghai state-owned capital funds. The Shanghai Biopharmaceutical M&A Fund represents a key initiative in Shanghai’s state-owned capital layout for the biopharmaceutical sector. Managed by SIIC Capital, a subsidiary of Shanghai Industrial Holdings (SIIC) Group, the fund aims to leverage the amplifying effect of state-owned capital, coordinate resources from “chain-leader” enterprises, and promote mergers, acquisitions, restructurings, and industrial upgrading within Shanghai’s pharmaceutical industry. The performance growth of Kanghua Biological serves, to some extent, as a validation of the M&A logic employed by state-owned capital funds.

Unlike traditional M&A in conventional industries, the Shanghai Biopharmaceutical Industry M&A Fund does not merely engage in simple “asset acquisitions.” Instead, it establishes an integrated investment and operational mechanism of “Fund + Industry + Empowerment.” This approach optimizes resource allocation through fund-controlled holdings, introduces R&D, clinical, and regional resources via strategic industrial layout, and continuously strengthens R&D investment and translation efficiency through post-investment empowerment.

Against the backdrop of profound adjustments in the global landscape of pharmaceutical innovation, the biopharmaceutical industry—characterized by long development cycles and high entry barriers—is transitioning from linear, single-enterprise R&D to systemic innovation driven by cross-entity collaboration. Capital is no longer merely a provider of funding; it has evolved into a deeper connector facilitating industrial innovation and development.

In recent years, M&A integration has become one of the central themes in the industry. Unlike the horizontal expansion pursued by industry leaders, Shanghai State-Owned Capital Funds distinguish themselves by leveraging funds as a capital link to deeply couple industrial resources, regional advantages, and target companies, thereby assuming the role of a platform organizer.

“Mergers and acquisitions (M&A) in the biopharmaceutical industry hinge not on the transaction itself, but on whether R&D, production capacity, and market channels can be effectively reintegrated post-deal,” pointed out an industry insider with extensive experience in pharmaceutical M&A. Many projects fail not because the wrong company was acquired, but due to the inability to establish a cohesive operational system after the acquisition. Biopharmaceutical M&A is shifting from a focus on “price and control” to a higher-dimensional paradigm of “system integration and restructuring.”

Shanghai’s state-owned capital funds are evolving in a structured manner according to industry logic. Benefiting from the deep empowerment provided by the Shanghai Biopharmaceutical Industry M&A Fund, Kanghua Biological has achieved a series of key milestones: its recombinant hexavalent norovirus vaccine, the first of its kind globally to enter clinical development, has initiated Phase I trials; its quadrivalent meningococcal conjugate vaccine has received approval for clinical trials; and its Shanghai R&D center has been officially unveiled. These developments demonstrate gradually emerging synergies.

However, the successful implementation in Shanghai of such a merger and acquisition integration mechanism, which demands exceptionally high organizational capabilities, is attributable to the city’s holistic systemic design for industrial development.

On one hand, there is sustained and ample capital investment. To date, Shanghai has established a matrix of state-owned M&A funds with a total scale of approximately RMB 80 billion, leveraging and participating in M&A transactions exceeding RMB 400 billion, covering multiple core industrial sectors such as biopharmaceuticals, semiconductors, and high-end equipment.

In terms of asset scale, Shanghai also possesses unique advantages. Official data shows that by the end of 2025, the total assets of Shanghai’s local state-owned enterprises (SOEs) reached RMB 32.5 trillion, hitting a record high and ranking first among all provincial-level local state-owned assets in China for consecutive years. This massive asset base means that Shanghai’s state-owned capital is well-positioned to assume multiple roles—“investor, organizer, and enterprise owner”—in mergers, acquisitions, and integration efforts.

On the other hand, there are the resource endowments accumulated over the long term. Shanghai’s continuously improving institutional supply has facilitated a closed-loop, mutually reinforcing ecosystem among policy, capital, and industry. As a result, Shanghai boasts a relatively comprehensive industrial layout, providing a solid foundation for “chain leader” enterprises to achieve upstream and downstream synergy.

It is precisely thanks to the systematic design of Shanghai’s industrial development that Kanghua Biological has become a typical case of performance improvement following a controlling acquisition by a Shanghai state-owned capital fund, which deeply led post-investment management. From “acquisition” to “effective management” and finally to “performance delivery,” each stage tests the M&A fund’s systematic post-investment management capability in coordinating industry, regional, and capital resources.

“Guiding Opinions on Further Promoting the High-Quality Development of Private Equity Investment Funds Supervised by the Municipal State-owned Assets Supervision and Administration Commission” (commonly known as the “16 Articles for Shanghai State-Owned Capital Funds”). The Guiding Opinions comprise three parts and 16 specific measures, centering on “market-oriented, rule-of-law-based, and professionalized” principles to systematically optimize fund management mechanisms and the fundraising-investment-management-exit framework, while advancing scientific delegation and appropriate decentralization of authority.

Following the release of the 16 Measures by Shanghai State-Owned Capital Funds, the market responded positively. Investment institutions have widely stated that the new policies send positive signals in areas such as exit mechanisms, performance evaluation, and incentives, which will further promote collaborative cooperation between market-oriented fund managers and Shanghai state-owned limited partners (LPs).

This shift is reshaping market expectations. On one hand, private capital is beginning to reassess the potential for synergy with state-owned funds, and joint investment cases are expected to gradually increase. On the other hand, high-quality targets are more willing to include state-owned funds in their shareholder structures to access the underlying industrial resources and policy support. The industry generally believes that the “16 Measures for Shanghai State-Owned Funds” will loosen restrictions on state-owned funds, further solidifying the institutional foundation for patient capital.

“This is not a piecemeal fine-tuning, but a systematic improvement of the institutional framework,” said Xie Zhaohuang, Executive Dean of the Shanghai State-owned Intelligence Technology Innovation and Collaborative Development Research Institute. In the past, state-owned capital funds exhibited, to some extent, a reluctance to lead investments, set valuations, make decisions, and provide value-added support. The new fund policies recently released by Shanghai’s state-owned assets authorities are precisely aimed at loosening constraints and recalibrating these critical aspects.

As Capital Gets Serious—Providing Funding, Resources, and Mechanisms—the Curtain Is Slowly Rising on Consolidation in the Biopharmaceutical Industry.